Eupraxia Pharmaceuticals reported that the Phase 1b/2a RESOLVE trial has produced 52‑week follow‑up data for EP‑104GI. Cohorts 5 and 6, the only groups that reached the 52‑week mark, achieved consistent, durable symptom relief and a favorable tolerability profile. Across more than 200 patient‑months of follow‑up, no serious adverse events or cases of oral or gastrointestinal candidiasis were observed, underscoring the safety of the once‑yearly injection.
EP‑104GI is engineered as a once‑yearly, localized injection that can be administered in tandem with routine annual endoscopies. The durability data reinforce the drug’s potential to improve adherence in a chronic disease that currently relies on more frequent therapies, such as Dupixent and Eohilia, which require monthly or bi‑monthly dosing.
The 52‑week results give the company a strong foundation as it moves into a randomized, placebo‑controlled Phase 2b study. The data support the hypothesis that EP‑104GI can deliver sustained symptom control, a key unmet need in eosinophilic esophagitis. With the U.S. market projected to reach $1.19 billion by 2030 and a CAGR of 19.4 %, the drug could capture a meaningful share of a rapidly expanding segment. The findings also validate Eupraxia’s Diffusphere™ platform, which is being applied to other indications such as osteoarthritis (EP‑104IAR).
CEO James A. Helliwell said, “These data further highlight the strong durability and tolerability profile of EP‑104GI, reinforcing its potential to become a convenient, once‑a‑year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies.” He added that the highest‑dose cohort delivered the largest improvements in tissue health outcomes and eosinophil reduction observed to date, with no additional safety concerns.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.